Investigators recently reported results from an early (Phase 1) trial of a candidate vaccine against the sexually transmitted bacterium, Chlamydia
SAFE launched at an ideal time, into a social ecosystem that has dwindling resources, through a medium that everyone understands and most likely already owns—the mobile device. Springing from the need to have equal access to testing, information, and sexual wellness support, SAFE democratizes access to quick, private, and readily available STD testing
Scientists at the US Centers for Disease Control and Prevention (CDC) have developed a model that identifies individuals at greatest risk of transmitting HIV, and helps to design strategies to reduce (and eventually eliminate) HIV transmission in the US.
Most know that STIs can be caused by bacteria, (such as gonorrhea, chlamydia, syphilis), viruses (such as herpes, HIV, hepatitis B), or protozoa (trichomonas). Fewer are familiar with another common bacterial STI – Mycoplasma genitalium, referred to here as Mg. Although Mg is a bacterium, it is difficult to grow in the laboratory, so diagnostic testing has been difficult to develop.
Special task force recommends all people with an increased risk of acquiring HIV take PrEP to protect themselves from infection.